Today's Daily Dose brings you news about disappointing trial results of Applied Genetic Technologies; near-term catalyst of Idera; stock offering of Marinus; disappointing Tourette syndrome trial results of Neurocrine Biosciences; bankruptcy proceedings of Synergy Pharma; Complete Response Letter for Mallinckrodt's pain drug, and promising data from Zynerba's phase II Fragile X Syndrome trial.
from RTT - Biotech https://ift.tt/2EhnxZ5
via IFTTT
No comments:
Post a Comment